The narcolepsy drug, developed by Irish company Jazz Pharmaceuticals, has a lower salt content than the current treatment Xyrem, making it more suitable for patients at risk of cardiovascular disease.
In a 200-patient phase III trial that finished in July, Jazz Pharmaceutical’s experimental drug was able to reduce the number of cataplexy attacks and the sleepiness of narcolepsy patients as compared to a placebo.
To continue reading this article click here.
Treatment with pitolisant is associated with reductions in excessive daytime sleepiness (EDS) and cataplexy over a 1-year period in patients with narcolepsy, according to research presented at World Sleep 2019, held September 20 to 25, 2019, in Vancouver, Canada.
Click here to continue reading this article.
COMING SOON !